Table 1.
Patient characteristics in groups with various severity of CAD.
| Variables | All Patients (n=37) | NO_CAD (n=8) | MM_CAD (n=10) | SVR_CAD (n=19) |
|---|---|---|---|---|
| Clinical Characteristics | ||||
| Age | 61 ± 7 | 60 ± 7 | 60 ± 8 | 63 ± 6 |
| Male, % | 86 | 75 | 100 | 84 |
| Weight, kg | 91 ± 18 | 91 ± 12 | 91 ± 14 | 92 ± 22 |
| Body Mass Index, kg/m2 | 29.4 ± 5.2 | 30.4 ± 3.9 | 28.4 ± 3.6 | 29.5 ± 6.3 |
| Body Surface Area, m2 | 2.1 ± 0.2 | 2.0 ± 0.2 | 2.1 ± 0.2 | 2.1 ± 0.2 |
| Black/White, % | 35/65 | 50/50 | 40/60 | 26/74 |
| Systolic Blood Pressure, mmHg | 131 ± 17 | 122 ± 13 | 132 ± 16 | 134 ± 18 |
| Diastolic Blood Pressure, mmHg | 74 ± 10 | 72 ± 12 | 73 ± 10 | 76 ± 10 |
| NYHA class I/II, (%) | 58/42 | 75/25 | 70/30 | 47/53 |
| Hypertension, % | 86 | 87.5 | 60 | 100 |
| Diabetes Mellitus, % | 46 | 25 | 50 | 53 |
| Medications | ||||
| AI/AT1RB, % | 46 | 12.5 | 40 | 63 |
| Beta-blockers, % | 62 | 50 | 50 | 74 |
| Diuretics, % | 40 | 62.5 | 20 | 42 |
| Nitrates, % | 27 | 25 | 10 | 37 |
| Calcium Blockers, % | 19 | 12.5 | 20 | 21 |
| Insulin/Oral Hypoglycemics, % | 35 | 25 | 30 | 42 |
| Statins, % | 65 | 50 | 50 | 79 |
| LV Invasive hemodynamic measurements | ||||
| LV End Systolic Pressure, mmHg | 128 ± 18 | 119 ± 15 | 126 ± 20 | 132 ± 18 |
| LV minimum diastolic pressure | 7.8 ± 4.2 | 7.4 ± 5.3 | 6.8 ± 3.7 | 8.5 ± 4.0 |
| LV End Diastolic Pressure, mmHg | 14.4 ± 5.6 | 13.8± 6.6 | 14.1 ± 5.7 | 15 ± 5.2 |
Values are mean±SD or percentage (if indicated).
NYHA= New York Heart Association; AI/AT1RB= angiotensin-converting enzyme inhibitor/ Angiotensin II type-1 receptor blocker; LV=left ventricular; CAD groups: no CAD (NO_CAD), mild-to-moderate CAD (MM_CAD), severe CAD (SVR_CAD).